EsoGuard
Commercial- Indications
- Esophageal cancer screening, Barrett's Esophagus detection
Company intelligence / Profile preview
Lucid Diagnostics
United Statesir.luciddx.com ↗
- Ownership
- Public · LUCD
- Development stage
- Commercial
01
Overview
Lucid Diagnostics markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer. Their flagship products are the EsoGuard® Esophageal DNA Test, which uses next-generation sequencing to detect abnormal cells in the esophagus, and the EsoCheck® device for non-invasive cell collection. These tools target patients with GERD or those at risk of Barrett’s esophagus to enable early intervention before progression to cancer. The company’s tests are commercially available in the United States.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- DeviceDNA-based diagnostic test (Next-generation sequencing)
- Industry
- Molecular Diagnostics
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Financials
- Market cap
- $156.6M
- Total revenue
- $1.5M
- Enterprise value
- $148.1M
Beyond the preview
Go deeper on Lucid Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lucid Diagnostics.